{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T22:29:12Z","timestamp":1780093752767,"version":"3.54.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.ygyno.2007.05.038","type":"journal-article","created":{"date-parts":[[2007,7,13]],"date-time":"2007-07-13T11:17:52Z","timestamp":1184325472000},"page":"558-566","source":"Crossref","is-referenced-by-count":93,"title":["A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia"],"prefix":"10.1016","volume":"106","author":[{"given":"L.D.","family":"Roman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wilczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.I.","family":"Muderspach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.F.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"O'Meara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Brinkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.M.","family":"Kast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Facio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Felix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aldana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2007.05.038_bib1","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199210293271804","article-title":"A cohort study of the risk of cervical intraepithelial neoplasia grade II or III in relation to papillomavirus infection","volume":"327","author":"Koutsky","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2007.05.038_bib2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2007.05.038_bib3","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2007.05.038_bib4","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2007.05.038_bib5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2007.05.038_bib6","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0020-7292(03)00225-X","article-title":"Cancer in women","volume":"82","author":"Pecorelli","year":"2002","journal-title":"Int. J. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2007.05.038_bib7","first-page":"954","article-title":"Effective screening programmes for cervical cancer in low- and middle-income developing countries","volume":"79","author":"Sankaranarayanan","year":"2001","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.ygyno.2007.05.038_bib8","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/j.1460-2075.1989.tb08594.x","article-title":"Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product","volume":"8","author":"Munger","year":"1989","journal-title":"EMBO J."},{"key":"10.1016\/j.ygyno.2007.05.038_bib9","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0092-8674(90)90409-8","article-title":"The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes degradation of p53","volume":"63","author":"Scheffner","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2007.05.038_bib10","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1128\/JVI.63.10.4417-4421.1989","article-title":"The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes","volume":"63","author":"Munger","year":"1989","journal-title":"J. Virol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/j.1460-2075.1989.tb03405.x","article-title":"Continued expression of HPV 16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV 16 plus EJ-ras","volume":"8","author":"Crook","year":"1989","journal-title":"EMBO J."},{"key":"10.1016\/j.ygyno.2007.05.038_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0167-5699(90)90050-J","article-title":"Heat shock proteins and the immune response","volume":"11","author":"Kaufmann","year":"1990","journal-title":"Immunol. Today"},{"key":"10.1016\/j.ygyno.2007.05.038_bib13","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/j.coi.2006.01.009","article-title":"Therapeutic cancer vaccines","volume":"18","author":"Srivastava","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib14","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1073\/pnas.0502313102","article-title":"Predicted highly expressed genes in archaeal genomes","volume":"102","author":"Karlin","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2007.05.038_bib15","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1084\/jem.178.4.1391","article-title":"Heat shock protein 70-associated peptides elicit specific cancer immunity","volume":"178","author":"Udono","year":"1993","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ygyno.2007.05.038_bib16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.278.5335.117","article-title":"Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations","volume":"278","author":"Tamura","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2007.05.038_bib17","doi-asserted-by":"crossref","first-page":"13146","DOI":"10.1073\/pnas.94.24.13146","article-title":"Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway","volume":"94","author":"Suzue","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ygyno.2007.05.038_bib18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8","article-title":"Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study","volume":"88","author":"Janetzki","year":"2000","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2007.05.038_bib19","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1200\/JCO.2002.09.134","article-title":"Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings","volume":"20","author":"Belli","year":"2002","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib20","first-page":"3235","article-title":"Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer","volume":"9","author":"Mazzaferro","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2007.05.038_bib21","first-page":"173","article-title":"Treatment of cervical intraepithelial neoplasia using the loop electrosurgical excision procedure","volume":"79","author":"Wright","year":"1992","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1158\/1078-0432.CCR-06-1450","article-title":"Interleukin-12 augments immunity to a melanoma peptide vaccine which correlates with time to relapse in patients with resected high risk disease","volume":"13","author":"Hamid","year":"2007","journal-title":"Clin. Can. Res."},{"key":"10.1016\/j.ygyno.2007.05.038_bib23","first-page":"483","article-title":"Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell -mediated immune responses to an HPV type 16 E7 peptide","volume":"11","author":"Kadish","year":"2002","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2007.05.038_bib24","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1158\/1078-0432.CCR-04-0241","article-title":"Immune responses to a class II helper peptide epitope in patients with stage III\/IV resected melanoma","volume":"10","author":"Wong","year":"2004","journal-title":"Clin. Can. Res."},{"key":"10.1016\/j.ygyno.2007.05.038_bib25","series-title":"PCR protocols: a guide to methods and applications","first-page":"356","article-title":"Detection and typing of genital human papillomaviruses","author":"Ting","year":"1990"},{"key":"10.1016\/j.ygyno.2007.05.038_bib26","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00019606-199412000-00012","article-title":"Comparison of the polymerase chain reaction and Southern blot analysis in detecting and typing human papilloma virus deoxyribonucleic acid in tumors of the lower female genital tract","volume":"3","author":"Monk","year":"1994","journal-title":"Diagn. Mol. Pathol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib27","first-page":"632","volume":"19","author":"Meyer","year":"1995","journal-title":"BioTechnology"},{"key":"10.1016\/j.ygyno.2007.05.038_bib28","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/0046-8177(93)90068-R","article-title":"Human papillomavirus type 6 in squamous cell carcinoma of the bladder and cervix","volume":"24","author":"Wilczynski","year":"1993","journal-title":"Human Pathol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/JCM.38.1.357-361.2000","article-title":"Improved amplification of genital human papillomaviruses","volume":"38","author":"Gravitt","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.ygyno.2007.05.038_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papilloma-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib32","first-page":"3406","article-title":"A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive","volume":"6","author":"Muderspach","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2007.05.038_bib33","first-page":"2103","article-title":"Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7","volume":"4","author":"Steller","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2007.05.038_bib34","first-page":"3676","article-title":"Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer","volume":"8","author":"Kaufmann","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2007.05.038_bib35","first-page":"5205","article-title":"Vaccinia-expressed human papillomavirus 16 and 18 E6 and E7 as a therapeutic vaccination for vulvar and vaginal intraepithelial neoplasia","volume":"9","author":"Baldwin","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2007.05.038_bib36","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.vaccine.2004.01.049","article-title":"Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16\/18 E6E7)","volume":"22","author":"Davidson","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2007.05.038_bib37","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1158\/1078-0432.CCR-03-0703","article-title":"Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination","volume":"10","author":"Smyth","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2007.05.038_bib38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/10430340460745757","article-title":"Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus","volume":"15","author":"Corona Gutierrez","year":"2004","journal-title":"Hum. Gene. Ther."},{"key":"10.1016\/j.ygyno.2007.05.038_bib39","first-page":"1028","article-title":"Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal cervical intraepithelial neoplasia: a Phase I study of ZYC101","volume":"8","author":"Klencke","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2007.05.038_bib40","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1067\/mob.2003.256","article-title":"Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA","volume":"188","author":"Sheets","year":"2003","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib41","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.vaccine.2004.05.013","article-title":"Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia","volume":"23","author":"Frazer","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.ygyno.2007.05.038_bib42","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00262-004-0501-4","article-title":"Phase I\/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia","volume":"53","author":"Hallez","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ygyno.2007.05.038_bib43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1046\/j.1365-2249.2000.01293.x","article-title":"Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis Bacille Calmette\u2013Guerin (BCG) hsp65 and HPV16 E7","volume":"121","author":"Chu","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib44","first-page":"193","article-title":"CoVal fusions: a therapeutic vaccine platform using heat shock proteins to treat chronic viral infection and cancer","volume":"116","author":"Neefe","year":"2004","journal-title":"Dev. Biol. (Basel.)"},{"key":"10.1016\/j.ygyno.2007.05.038_bib45","series-title":"Presented at the 36th Annual Meeting of the Society of Gynecologic Oncologists, Miami, Florida","article-title":"Heat shock protein (HSP)-based immunotherapy (HspE7) for treatment of CIN III (NCI 5850, NYGOG)","author":"Einstein","year":"2005"},{"key":"10.1016\/j.ygyno.2007.05.038_bib46","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1158\/1078-0432.CCR-03-0498","article-title":"Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes","volume":"10","author":"Warrino","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2007.05.038_bib47","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1119>3.0.CO;2-C","article-title":"Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes","volume":"91","author":"van der Burg","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2007.05.038_bib48","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/0008-5472.CAN-04-0831","article-title":"Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T cell immunity against early antigens E2 and E6","volume":"64","author":"de Jong","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2007.05.038_bib49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ygyno.2005.07.099","article-title":"Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study","volume":"99","author":"Sarkar","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib50","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.bjc.6602679","article-title":"T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia","volume":"93","author":"Steele","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2007.05.038_bib51","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0029-7844(98)00245-2","article-title":"Natural history of cervical squamous intraepithelial lesions: a meta-analysis","volume":"92","author":"Melnikow","year":"1998","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2007.05.038_bib52","first-page":"796","article-title":"Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica","volume":"1911","author":"Herrero","year":"2005","journal-title":"JID"},{"key":"10.1016\/j.ygyno.2007.05.038_bib53","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1525-1438.2006.00458.x","article-title":"Human papilloma virus-specific viral types are common in Mexican women affected by cervical lesions","volume":"16","author":"Pina-Sanchez","year":"2006","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2007.05.038_bib54","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/156800907780006869","article-title":"Mechanisms used by human papillomavirus to escape the host immune response","volume":"7","author":"Kanodia","year":"2007","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ygyno.2007.05.038_bib55","doi-asserted-by":"crossref","first-page":"7172","DOI":"10.4049\/jimmunol.174.11.7172","article-title":"Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation","volume":"174","author":"Fausch","year":"2005","journal-title":"J. Immunol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580700340X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082580700340X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T04:05:34Z","timestamp":1629345934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082580700340X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S009082580700340X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2007.05.038","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}